Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 18/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 18/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 18/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 17/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 17/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 17/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 17/20 | 0.48 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008217 | 0.88 | PRKAG1 (0.56) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3380509 | 0.87 | FGFR1 (0.58) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3386730 | 0.84 | PDPK1 (0.67) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL3384896 | 0.82 | PRKAG1 (0.49) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL14574212 | 0.81 | KDM4E (0.63) | PRKAG1PRKAA1PRKAB1AXL | |
| SCHEMBL176936 | 0.81 | PRKAG1 (0.55) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12879075 | 0.81 | PRKAG1 (0.46) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL12090187 | 0.79 | MAPK1 (0.50) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL7379535 | 0.79 | MAP2K4 (0.61) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 | |
| SCHEMBL30075258 | 0.79 | IDO1 (0.62) | PRKAG1PRKAA1PRKAB1PRKAB2PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103596937-A | Substituted benzamide derivatives | HOFFMANN LA ROCHE | 2014-02-19 | — | — | CN | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009084695-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | PRKAG1 236/4885PRKAA1 34/4885PRKAB1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.